NO - Besoin d'assistance
NO - Besoin d'assistance
NO - Besoin d'assistance
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Observational epidemiological surveys (WG 3) page 44<br />
_________________________________________________________________________________________<br />
Table 26: Intervention studies<br />
Authors<br />
Country<br />
LINXIAN 1<br />
China<br />
Blot et al., 1993<br />
LINXIAN 2<br />
China<br />
Li et al., 1993<br />
LINXIAN 3<br />
China<br />
Mark et al., 1994<br />
ATBC<br />
Finland<br />
The ATBC cancer<br />
prevention study group,<br />
1994<br />
CARET<br />
USA<br />
Omenn et al., 1996-b<br />
PHYSICIANS' HEALTH<br />
STUDY<br />
USA<br />
Hennekens et al., 1996<br />
THE WOMEN’S<br />
HEALTH STUDY<br />
Lee et al., 1999<br />
THE POLYP<br />
PREVENTION STUDY<br />
USA<br />
Greenberg et al.<br />
1994,<br />
THE AUSTRALIAN<br />
POLYP PREVENTION<br />
STUDY<br />
Australie<br />
Mac Lennan et al.<br />
1995,<br />
SKIN CANCER<br />
PREVENTION STUDY<br />
(SCPS)<br />
Greenberg et al., 1990<br />
Subjects Treatment Follow-up Endpoints<br />
29584 general<br />
population in<br />
Linxian<br />
compliance 93%<br />
C: vit C+ molybdenum<br />
120mg+30µg<br />
D: β-carot+vit E+Se<br />
15mg+30mg+50mg<br />
5 years<br />
and 3<br />
months<br />
Mortality all<br />
causes, all cancers<br />
3318 subjects from<br />
Plasma level 1.5 µmol/L (14.5x)<br />
14 vitamins + 12 minerals at 2-3 6 years oesophagus/gastric<br />
the above cohort x RDA among them β-carotene,<br />
cardia cancer<br />
with œsophagus (15mg/day), vit A, E, 60 IU, C,<br />
mortality and<br />
dysplasia 180mg, B1,B2,B6, B12, folic ac,<br />
biotin, Ca, Se, Mb, Zn, Mn, I,<br />
Cu, Fe.<br />
incidence<br />
same study as above<br />
id 6 years oesophagus<br />
dysplasia reversion<br />
29000 intense<br />
smokers<br />
compliance 93%<br />
drop out 31%<br />
18314 smokers, exsmokers,<br />
asbestos<br />
exposed<br />
compliance 93%<br />
drop out 35%<br />
22071 physicians<br />
compliance 78%<br />
drop out 20%<br />
39876 women aged<br />
≥45<br />
864 subjects with<br />
sporadic adénomas<br />
removed in the<br />
previous 3 months<br />
compliance 82%<br />
drop out 13%<br />
390 subjects with<br />
>1 polyp removed<br />
at day 0<br />
drop out 28%<br />
1720 subjects with<br />
skin cancer recently<br />
removed<br />
compliance 80%<br />
1-β-carot. 20mg/day<br />
plasma level: 5.3 µmol/L (17.6x)<br />
2-vit. E 50mg/day<br />
plasma level: 42.5 µmol/L (1.5x)<br />
3-1+2<br />
β-carot. 30mg/day + 25000 UI<br />
vit. A<br />
plasma level: 3.6 µmol/L (12.4x)<br />
β-carot. 50mg/day<br />
plasma level: 1.7 µmol/L (4x)<br />
50mg on alternate days for 2.1<br />
years<br />
plasma level:0.70 mg/dL vs 0.20<br />
compliance 87%<br />
1-β-carotene 25mg/day<br />
plasma level 1.1 µmol/L (2.7x)<br />
2-vitamin C 1g/day + vit. E<br />
400mg/day<br />
plasma level 30.6 µmol/L (1.4x)<br />
3-=1+2<br />
β-carotene 20mg<br />
no information on plasma levels<br />
β-carot. 50mg/day<br />
plasma level 3.3 µmol/L (10x)<br />
5 to 8 years lung and other<br />
cancers incidence<br />
Mean:4<br />
years<br />
Mean: 12<br />
years<br />
and other cancers<br />
incidence<br />
lung cancer (and<br />
CVD) incidence<br />
4.1 year cancer (and CVD)<br />
incidence<br />
4 years new adenomas<br />
24 et 48<br />
months<br />
reocurrence of<br />
small and large<br />
adenomas<br />
Mean: 4.3 secondary nonmelanoma<br />
skin<br />
cancer
Change language